Cargando…
A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β(1)-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease
The purpose of this study was to compare the safety and efficacy of the short-acting β(1)-receptor blocker, landiolol hydrochloride (0.06 and 0.125-mg/kg), to placebo during coronary computed tomography angiography (CTA) in a phase 2 dose-finding study. A total of 183 patients suspected of having is...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722440/ https://www.ncbi.nlm.nih.gov/pubmed/23784548 http://dx.doi.org/10.1007/s10554-013-0253-3 |